Combat the spread of infectious disease

By BioGX

The past few months has shown that a team’s rapid response to expediting an assay globally, dedicated to the detection of SARS-CoV-2, is possible. BioGX, in a long-term partnership with Becton, Dickinson and Company, has submitted a test to the FDA for emergency use authorisation (EUA) in the US, in parallel to CE-IVD approval. In these challenging times, laboratories around the world have an urgent need for an easy-to-use, reliable test to detect SARS-CoV-2 to determine if patients have contracted COVID-19. Authorisation to use these tests worldwide would increase access to highly reliable results.

Enter your details below to view the free white paper

By downloading this White Paper, you acknowledge that may share your information with our white paper partners/sponsors who may contact you directly with information on their products and services.

Visit our Privacy Policy for more information about our services, how Business Trade Media International Limited may use, process and share your personal data, including information on your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.